bupropion and topiramate

bupropion has been researched along with topiramate in 42 studies

Research

Studies (42)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (26.19)29.6817
2010's25 (59.52)24.3611
2020's6 (14.29)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Antonsson, M; Bengtsson, O; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Jerndal, G; Wan, H; Winiwarter, S1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Kennedy, SH; Mancini, DA; McCann, S; McIntyre, RS; Sagman, D; Srinivasan, J1
Li, Z; Maggard, M; Maglione, M; Mojica, WA; Morton, SC; Shekelle, PG; Shugarman, L; Solomon, V; Suttorp, M; Tu, W1
Carter, GT; Han, JJ; McCrory, MA; Yudkowsky, MP1
Geddes, J; Macritchie, K; Vasudev, K; Watson, S; Young, A1
Ait-Daoud, N; Breland, AB; Johnson, BA; Lynch, WJ; Marzani-Nissen, GR; Penberthy, JK1
Dannon, PN; Gonopolsky, Y; Kotler, M; Lowengrub, K; Musin, E1
Al-Zaman, Y; Aylwin, S1
Bras, M1
Kapoor, S1
Bańka, K; Barczyński, B; Buszewicz, G; Mądro, R; Mróz, T; Tutaj, K; Tutka, P; Wielosz, M; Łuszczki, JJ1
Bray, GA; Ryan, DH1
Goldfine, AB; Hiatt, WR; Thomas, A1
Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J1
Nakazato, M; Ueno, H1
Aldhoon-Hainerová, I; Hainer, V1
Hainer, V1
Cunningham, JW; Wiviott, SD1
Goutier, W; Kloeze, M; McCreary, AC1
Citrome, L1
Rubio, MA1
Dahiya, N; Kakkar, AK1
Fujioka, K1
McCall, WV; Rosenquist, PB; Surya, S1
Bragg, R; Crannage, E1
Etminan, M; Mikelberg, FS; Symes, RJ1
Megyeri, J; Nuffer, W; Trujillo, JM1
Halpern, B; Mancini, MC1
Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH1
Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M1
Brown, SA; Izzy, M; Watt, KD1
Lee, SY; Tak, YJ1
Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S1
Ciccarone, D; Shoptaw, S1
Correa, OMT; Doretto-Silva, L; Morreale, S; Nassis, C; Petri, G; Santos, JFRD; Scudeler, MA; Veridiano, JM1
Hill, A; Levi, J; Venter, F; Wang, J1

Reviews

21 review(s) available for bupropion and topiramate

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Pharmacological and surgical treatment of obesity.
    Evidence report/technology assessment (Summary), 2004, Issue:103

    Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric Bypass; Gastroplasty; Humans; Lactones; Lipase; Obesity; Orlistat; Phentermine; Topiramate

2004
Topiramate for acute affective episodes in bipolar disorder.
    The Cochrane database of systematic reviews, 2006, Jan-25, Issue:1

    Topics: Affective Disorders, Psychotic; Antimanic Agents; Bipolar Disorder; Bupropion; Depressive Disorder; Fructose; Humans; Randomized Controlled Trials as Topic; Topiramate

2006
Treating smoking dependence in depressed alcoholics.
    Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism, 2006, Volume: 29, Issue:3

    Topics: Alcoholism; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depressive Disorder; Fructose; Humans; Nicotine; Psychotherapy, Group; Smoking Cessation; Topiramate

2006
Emerging concepts in the medical and surgical treatment of obesity.
    Frontiers of hormone research, 2008, Volume: 36

    Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide

2008
[Psychopharmacotherapy in psychiatric comorbidities among patients with chronic pain].
    L'Encephale, 2007, Volume: 33, Issue:Pt 3

    Topics: Amines; Analgesics; Anticonvulsants; Bupropion; Chronic Disease; Cyclohexanecarboxylic Acids; Dopamine Uptake Inhibitors; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Lamotrigine; Mental Disorders; Pain; Topiramate; Triazines

2007
Recent advancements in drug treatment of obesity.
    Clinical medicine (London, England), 2012, Volume: 12, Issue:5

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss

2012
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3

    Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate

2014
Tolerability and safety of the new anti-obesity medications.
    Drug safety, 2014, Volume: 37, Issue:9

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate

2014
Overview of new antiobesity drugs.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss

2014
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
    Clinical cardiology, 2014, Volume: 37, Issue:11

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Fructose; Heart; Humans; Naltrexone; Obesity; Phentermine; Topiramate

2014
Drug treatment of obesity: current status and future prospects.
    European journal of internal medicine, 2015, Volume: 26, Issue:2

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Drug Combinations; Drug Therapy, Combination; Fructose; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate

2015
Safety and tolerability of medications approved for chronic weight management.
    Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss

2015
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:5

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss

2016
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Expert opinion on drug safety, 2017, Volume: 16, Issue:1

    Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate

2017
Practical Use of Pharmacotherapy for Obesity.
    Gastroenterology, 2017, Volume: 152, Issue:7

    Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain

2017
Gender-related issues in the pharmacology of new anti-obesity drugs.
    Obesity reviews : an official journal of the International Association for the Study of Obesity, 2019, Volume: 20, Issue:3

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Liraglutide; Male; Naltrexone; Obesity; Patient Selection; Sex Factors; Topiramate; Treatment Outcome; Weight Loss

2019
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
    Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:5

    Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liver Transplantation; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Translational Science, Biomedical

2021
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Current obesity reports, 2021, Volume: 10, Issue:1

    Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss

2021
Long-term effects of weight-reducing drugs in people with hypertension.
    The Cochrane database of systematic reviews, 2021, 01-17, Volume: 1

    Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet, Reducing; Drug Combinations; Female; Fructose; Humans; Hypertension; Lactones; Male; Middle Aged; Naltrexone; Orlistat; Phentermine; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Time; Topiramate

2021
Understanding Stimulant Use and Use Disorders in a New Era.
    The Medical clinics of North America, 2022, Volume: 106, Issue:1

    Topics: Adrenergic alpha-2 Receptor Antagonists; Adult; Anticonvulsants; Behavior Therapy; Bupropion; Central Nervous System Stimulants; Cocaine-Related Disorders; Cognitive Dysfunction; Comorbidity; Dopamine Uptake Inhibitors; Female; Humans; Illicit Drugs; Male; Mental Disorders; Methamphetamine; Mirtazapine; Neurobiology; Neurodegenerative Diseases; Opiate Overdose; Substance Withdrawal Syndrome; Topiramate; Transgender Persons; United States

2022

Trials

1 trial(s) available for bupropion and topiramate

ArticleYear
Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study.
    Bipolar disorders, 2002, Volume: 4, Issue:3

    Topics: Acute Disease; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Bupropion; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fructose; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Single-Blind Method; Topiramate; Treatment Outcome

2002

Other Studies

20 other study(ies) available for bupropion and topiramate

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
    Journal of medicinal chemistry, 2009, Oct-22, Volume: 52, Issue:20

    Topics: Animals; Blood-Brain Barrier; Brain; Extracellular Fluid; Humans; Linear Models; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:3

    Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution

2011
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Topiramate for weight reduction in Duchenne muscular dystrophy.
    Muscle & nerve, 2005, Volume: 31, Issue:6

    Topics: Adolescent; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Appetite; Body Weight; Bupropion; Caloric Restriction; Dose-Response Relationship, Drug; Drug Administration Schedule; Fructose; Humans; Male; Muscular Dystrophy, Duchenne; Obesity; Topiramate; Treatment Outcome

2005
12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:6

    Topics: Adolescent; Adult; Analysis of Variance; Bupropion; Delayed-Action Preparations; Drug Therapy; Fluvoxamine; Follow-Up Studies; Fructose; Gambling; Humans; Israel; Male; Middle Aged; Naltrexone; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Psychopharmacology; Recurrence; Reproducibility of Results; Surveys and Questionnaires; Time Factors; Topiramate

2007
Strategies to control antipsychotic-induced weight gain.
    Psychoneuroendocrinology, 2008, Volume: 33, Issue:8

    Topics: Anti-Obesity Agents; Antipsychotic Agents; Awareness; Body Weight; Bupropion; Clinical Competence; Fructose; Humans; Hypoglycemic Agents; Melatonin; Metformin; Obesity; Topiramate; Treatment Outcome; Weight Gain

2008
Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice.
    European journal of pharmacology, 2011, Jan-15, Volume: 650, Issue:2-3

    Topics: Animals; Anticonvulsants; Brain; Bupropion; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Electroshock; Felbamate; Fructose; Injections, Intraperitoneal; Lamotrigine; Male; Mice; Motor Activity; Phenylcarbamates; Propylene Glycols; Psychomotor Performance; Rotarod Performance Test; Seizures; Topiramate; Triazines

2011
Drug treatment of obesity.
    The Psychiatric clinics of North America, 2011, Volume: 34, Issue:4

    Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Child; Drug Approval; Drug Combinations; Energy Intake; Exenatide; Female; Fructose; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lactones; Male; Metformin; Naltrexone; Narcotic Antagonists; Obesity; Orlistat; Patient Compliance; Peptides; Randomized Controlled Trials as Topic; Sympathomimetics; Topiramate; United States; United States Food and Drug Administration; Venoms

2011
What cost weight loss?
    Circulation, 2012, Mar-06, Volume: 125, Issue:9

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; Phentermine; Risk Assessment; Risk Factors; Topiramate; Weight Loss

2012
Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids.
    Addiction biology, 2016, Volume: 21, Issue:2

    Topics: Acamprosate; Analysis of Variance; Animals; Antidiuretic Hormone Receptor Antagonists; Bupropion; Dose-Response Relationship, Drug; Fructose; Indoles; Male; Motor Activity; Naltrexone; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats, Wistar; Taurine; Tobacco Use Cessation Devices; Topiramate

2016
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
    International journal of clinical practice, 2014, Volume: 68, Issue:12

    Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss

2014
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2014, Volume: 61, Issue:10

    Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Europe; Fructose; Humans; Naltrexone; Obesity; Phentermine; Product Surveillance, Postmarketing; Topiramate; United States; United States Food and Drug Administration

2014
Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depression in a Patient With an Intracranial Space-Occupying Lesion: A Case Report of Safety.
    The journal of ECT, 2016, Volume: 32, Issue:1

    Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Brain Neoplasms; Bupropion; Depressive Disorder, Major; Female; Fructose; Humans; Magnetic Resonance Imaging; Middle Aged; Pinealoma; Recurrence; Topiramate; Transcranial Magnetic Stimulation

2016
Review of pharmacotherapy options for the management of obesity.
    Journal of the American Association of Nurse Practitioners, 2016, Volume: 28, Issue:2

    Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States

2016
Risk of angle-closure glaucoma with bupropion and topiramate.
    JAMA ophthalmology, 2015, Volume: 133, Issue:10

    Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Bupropion; Case-Control Studies; Databases, Factual; Esomeprazole; Female; Fructose; Glaucoma, Angle-Closure; Humans; Intraocular Pressure; Male; Middle Aged; Odds Ratio; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Tonometry, Ocular; Topiramate; Young Adult

2015
Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats.
    Einstein (Sao Paulo, Brazil), 2022, Volume: 20

    Topics: Animals; Bupropion; Humans; Male; Naltrexone; Obesity; Rats; Rats, Wistar; Subcutaneous Fat; Topiramate

2022
Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.
    Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:5

    Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Health Care Costs; Health Services Accessibility; Liraglutide; Naltrexone; Orlistat; Phentermine; Topiramate

2023